SCHEMBL2475458

SCHEMBL2475458

CC#CC1CNC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL31506646 0.97
SCHEMBL17039188 0.78
SCHEMBL2600236 0.75
SCHEMBL24060807 0.71 ALDH1A1 (0.32)
SCHEMBL4551162 0.71
SCHEMBL17036510 0.69
SCHEMBL17039192 0.69
Hydrochloric Acid SCHEMBL17080481 0.67
SCHEMBL18975190 0.66
SCHEMBL1987796 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2215085-B1 PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS ASTRAZENECA AB (SE) 2011-09-07 EP claimed
WO-2023235433-A1 BICYCLIC INHIBITORS OF IRAK RIGEL PHARMACEUTICALS, INC. (US) 2023-12-07 WO disclosed
US-9828396-B2 Alkyne compounds for treatment of complement mediated disorders ACHILLION PHARMACEUTICALS, INC. (US) 2017-11-28 US disclosed
US-20150239868-A1 Alkyne Compounds for Treatment of Complement Mediated Disorders ACHILLION PHARMACEUTICALS, INC. (US) 2015-08-27 US disclosed